July 24, 2019 10:52 AM EDT

GSK culls more respiratory drugs out of PhII as focus shifts to cancer

John Carroll

Editor & Founder

GlaxoSmithKline isn’t done with whittling down their respiratory drug and vaccines portfolios.

The pharma giant unceremoniously scrapped two more respiratory drugs

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

GSK culls more respiratory drugs out of PhII as focus shifts to cancer

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

The next generation of AI biotechs is here. Can they deliver on the hype?

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

GSK culls more res­pi­ra­to­ry drugs out of PhII as fo­cus shifts to can­cer

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Sanders press­es phar­ma lead­ers to change stance on Pan­dem­ic Ac­cord pro­pos­als

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

GSK culls more respiratory drugs out of PhII as focus shifts to cancer

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

The next generation of AI biotechs is here. Can they deliver on the hype?

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag